This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Peregrine Pharma Cancer Drug Unmasked by Independent Review

Content on this page requires a newer version of Adobe Flash Player.



Get Adobe Flash player

TUSTIN, Calif. (TheStreet) --Peregrine Pharmaceuticals' (PPHM) experimental lung cancer drug bavituximab looks like a bust.

Updated results from a mid-state lung cancer study were released Friday morning revealing bavituximab ("bavi") to be not much more than a placebo. Eighty-six lung cancer patients treated with bavi plus carboplatin and paclitaxel (chemo) reported an overall response rate of 25% compared to an overall response rate of 23% for patients treated with carboplatin and paclitaxel alone.

Bavi delayed tumor progression or death by 6.7 months compared to 6.4 months for patients in the control arm -- a difference of just 9 days.

Peregrine shares were down 18 cents, or 20%, to 72 cents in Friday trading.

Friday's disappointing bavi data upend a more positive report from the same study released last December when Peregrine reported a 39% response rate in bavi-treated patients compared to 26% in the control arm.

What happened?

The new results come from a "central" or independent review of the phase II study. When analyzing clinical trial results always give more weight to independent analysis over similar looks at data conducted by investigators actually participating in the trial. Regulators give more weight to independent analysis because it's more objective.

While Peregrine didn't specify, December's results were almost certainly derived from investigators interpreting patient scans. That helps explain why their reported response rates were higher -- and skewed towards bavi. Additional bias is injected into the study because its open label, meaning doctors and patients know who is receiving bavi plus chemo or just chemo alone.

Be extra wary of open-label clinical trials, even those that are randomized and controlled.

You can see further evidence of investigator bias towards bavi in today's progression-free survival results. As I said above, centrally reviewed PFS was essentially identical at 6.7 months for bavi versus 6.4 months for control. Investigator-assessed PFS was 5.8 months for bavi versus 4.6 months for the control arm.

Peregrine says the central review determination of a 6.4-month PFS benefit for the control arm is abnormally high, making the results difficult to interpret. But of course, the central reviewers also came back with a higher PFS for bavi, which the company fails to mention even though it works in their favor.

An assessment of overall survival in this study is pending.

I previously dissected the December results of the bavi study, worth a read because many of the questions I raised turned out to work against Peregrine.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs